bluuebunny/crossref_metadata_2025_split huggingface dataset:
Abstract OT3-05-01: A randomized double-blind phase III clinical trial of neoadjuvant chemotherapy (NAC) with atezolizumab or placebo in patients (pts) with triple negative breast cancer (TNBC) followed by adjuvant atezolizumab or placebo: NSABP B-59/GBG 96-GeparDouze
Authors: Geyer CE , Loibl S , Rastogi P , Seiler S , Costantino JP , Nekljudova VN , Cortazar P , Lucas PC , Denkert C , Mamounas EP , Jackisch C , Wolmark N 
Published: May 2019

Abstract
Background:
TNBC is associated with higher percentages of pathological complete response (pCR) to neoadjuvant chemotherapy (NAC), and women with a pCR have a favorable prognosis. However, Liedtke (2008) and Loibl (2017) found that women with residual disease have a substantially higher risk of recurrence than women with other subtypes of breast cancer. Additionally, Adams (2017) and Schmid (2017) found that therapeutic blockade of PD-L1 binding by atezolizumab has resulted in relevant anti-tumor efficacy.
Methods:
Design
This is a phase III, double blind, placebo-control trial evaluating neoadjuvant atezolizumab with NAC followed by adjuvant atezolizumab in TNBC. Pts are stratified by region (North America; Europe), tumor size (1.1-3.0cm; &gt;3.0cm), AC/EC schedule (q2w; q3w), and nodal status (positive; negative), then randomized 1:1 to receive atezolizumab/placebo 1200 mg IV every 3 wks concurrently with both sequential regimens of weekly paclitaxel 80 mg/m2 IV for 12 doses with every 3-wk carboplatin AUC of 5 IV for 4 doses followed by AC/EC every 2-3 wks (per investigator discretion) for 4 cycles. Following surgery, pts resume atezolizumab/placebo 1200 mg IV every 3 wks as adjuvant therapy for 6 months. Radiotherapy based on local standards is co-administered with atezolizumab/placebo.
Eligibility criteria
Centrally-confirmed ER-neg, PR-neg, HER2-neg invasive breast cancer by ASCO/CAP guidelines. Primary tumor must be stage T2 or T3 if cN0 or cN1 with negative biopsy or T1c, T2, or T3 if cN1 with positive biopsy or cN2 or cN3. LVEF &gt;55% and no significant cardiac history.
Statistical methods
Co-primary endpoints are event-free survival (EFS) and pCR breast/nodes. Secondary endpoints include pCR breast, overall survival, distant disease-free survival, safety and toxicity. Trial is an academic collaboration between NSABP and GBG with support from Genentech/Roche.
NCT03281954
Support: Genentech/Roche
Citation Format: Geyer, Jr. CE, Loibl S, Rastogi P, Seiler S, Costantino JP, Nekljudova VN, Cortazar P, Lucas PC, Denkert C, Mamounas EP, Jackisch C, Wolmark N. A randomized double-blind phase III clinical trial of neoadjuvant chemotherapy (NAC) with atezolizumab or placebo in patients (pts) with triple negative breast cancer (TNBC) followed by adjuvant atezolizumab or placebo: NSABP B-59/GBG 96-GeparDouze [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr OT3-05-01.
Abstract P1-03-09: The breast cancer care continuum in Tanzania: From accessing care for breast concerns to cancer diagnosis and treatment
Authors: Rositch AF , Chao CA , Masalu N , Visvanathan K 
Published: May 2019

Abstract
Background: Tanzania, like many low to middle income countries, has developed their first ever national guidelines focusing on early diagnosis of breast cancer to combat the high fatality rates. Thus, one component of the “Time to A.C.T.” study sought to provide critical information on women presenting to a health facility who might need clinical breast examination per the new guidelines and ultimately how many of these women were diagnosed and treated for breast cancer.
Methods: In this retrospective cohort study, data were abstracted from 777 medical charts from three health facilities spanning the health system hierarchy (district n=103, regional n=64, and zonal n=610 hospitals) in Mwanza, Tanzania. Charts were identified from the departments of oncology, surgery, gynecology, obstetrics and emergency medicine, and focused on women aged 30 and older who were seeking or receiving care related to any “breast concern” from January 2015 to April 2018.
Results: The median age of women seeking care for breast concerns was 43 years (IQR: 34-54). Women most commonly presented with complaints of swelling (43%), a palpable lump (27%), or pain (24%) of the breast or nipple. Ultimately, 26% of these care-seeking women were diagnosed with breast cancer (including DCIS=2, invasive ductal or lobular cancer=121, and metastatic cancer =15), of whom 73% were pathologically confirmed. Treatment data were available for only 79 women with breast cancer: 24 had surgery only, 33 had chemotherapy only, 21 had surgery and chemotherapy, and 1 woman had surgery, chemotherapy and radiation.
Conclusions: This study increases our understanding of the health services needs associated with Tanzania's commitment to down stage breast cancer through early detection and treatment. Almost a third of women who presented with a breast concern were diagnosed with breast cancer. Although this likely reflects the fact the majority of medical charts were identified at a zonal hospital that has the most capacity for cancer diagnosis and treatment, it also highlights the importance of getting women into care, proper referrals and ultimately diagnosis and treatment. This information on who seeks care, why, and where will help appropriately allocate and scale up capacity for breast cancer care.
Citation Format: Rositch AF, Chao CA, Masalu N, Visvanathan K. The breast cancer care continuum in Tanzania: From accessing care for breast concerns to cancer diagnosis and treatment [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P1-03-09.
Abstract P1-04-02: Not presented
Authors: Lin C-Y , Hazar-Rethinam M , Thangavelu P , Dray E , Duijf PH 
Published: May 2019

Abstract
This abstract was not presented at the conference.
Citation Format: Lin C-Y, Hazar-Rethinam M, Thangavelu P, Dray E, Duijf PH. Not presented [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P1-04-02.
Abstract P1-06-01: Regulation of BRCA1 by SIRT2
Authors: Minten EV , Zhang H , Li C , Head PE , Yu DS 
Published: May 2019

Abstract
We are constantly exposed to a variety of both external and internal DNA damaging agents, such as UV light from the sun and reactive oxygen species created as by-products of aerobic respiration. As a result, our DNA accumulates thousands of instances of damage per cell per day. DNA damage response (DDR) pathways, which include DNA repair and cell-cycle checkpoints, are responsible for the repair of DNA damage and are critical for protecting against mutagenesis and maintaining genome integrity. DNA double-stranded breaks (DSBs) are the most deleterious type of DNA damage and are repaired by one of two pathways: Non-homologous end-joining (NHEJ), an error-prone mechanism of repair active throughout the entire cell cycle, or homologous recombination (HR), considered to be an 'error-free' method for DSB repair that occurs in the S and G2 phases of the cell cycle. Deficiencies in NHEJ or HR can result in genomic instability via genomic incorporation of chromosomal aberrations, which can ultimately lead to an increased risk of cancer. However, in many cases, the mechanisms by which defects in these pathways lead to an increased risk of developing cancer is unknown, making preventative care and treatment of resulting cancers more difficult. Breast Cancer 1 (BRCA1), an established tumor suppressor, is a protein necessary for the proper repair of DNA DSBs through the HR pathway. Defects in BRCA1, whether genetically inherited or spontaneously developed, have been linked to different types of cancer in both men and women, including breast, ovarian, and pancreatic cancer. Yet, the regulation of BRCA1 in HR is not well understood and thus highlights a major a gap in our understanding of how deficiencies in HR contribute to the development of cancer. Our lab has discovered that SIRT2, a class III NAD+ dependent histone deacetylase and putative human tumor suppressor, plays a crucial role in the DDR and repair of DNA DSBs. We have shown that depletion of SIRT2 impairs HR and increases cell sensitivity to ionizing radiation in a deacetylase-dependent manner. A mass spectrometry analysis showed SIRT2 interacts with several proteins involved in DDR, including BRCA1. We validated the interaction between SIRT2 and BRCA1 and found SIRT2 deacetylates BRCA1 both in vitro and in cells. Depletion of SIRT2 and subsequent deacetylation of BRCA1 decreases BRCA1 protein levels in cells, impairing HR. Our results show SIRT2 is a novel regulator of BRCA1 and is critical for the repair of DNA DSBs through HR. These findings provide invaluable insights into how to exploit the interplay between SIRT2 and BRCA1 as a novel therapeutic approach for the prevention and treatment of cancer.
Citation Format: Minten EV, Zhang H, Li C, Head PE, Yu DS. Regulation of BRCA1 by SIRT2 [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P1-06-01.
Abstract P1-06-09: Withdrawn
Authors: Yu Y , Zhen Y , Zhang Y 
Published: May 2019

Abstract
This abstract was withdrawn by the authors.
Citation Format: Yu Y, Zhen Y, Zhang Y. Withdrawn [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P1-06-09.
Abstract P1-08-01: Withdrawn
Authors: Schoemaker MJ , Nichols HB , Wright LB , Brook MN , Jones ME , O'Brien KM , Adami H-O , Baglietto L , Bernstein L , Bertrand KA , Boutron-Ruault M-C , Chen Y , Connor AE , Dorronsoro M , Dossus L , Eliassen AH , Giles GG , Gram IT , Hankinson SE , Kaaks R , Key TJ , Kirsh VA , Kitahara CM , Koh W-P , Larsson SC , Linet MS , Ma H , Masala G , Merritt MA , Milne RL , Overvad K , Ozasa K , Palmer JR , Riboli E , Rohan TE , Sadakane A , Sund M , Tamimi RM , Trichopoulou A , Ursin G , Van Gils CH , Visvanathan K , Weiderpass E , Willett WC , Wolk A , Yuan J-M , Zeleniuch-Jacquotte A , Sandler DP , Swerdlow AJ 
Published: May 2019

Abstract
This abstract was withdrawn by the authors.
Citation Format: Schoemaker MJ, Nichols HB, Wright LB, Brook MN, Jones ME, O'Brien KM, Adami H-O, Baglietto L, Bernstein L, Bertrand KA, Boutron-Ruault M-C, Chen Y, Connor AE, Dorronsoro M, Dossus L, Eliassen AH, Giles GG, Gram IT, Hankinson SE, Kaaks R, Key TJ, Kirsh VA, Kitahara CM, Koh W-P, Larsson SC, Linet MS, Ma H, Masala G, Merritt MA, Milne RL, Overvad K, Ozasa K, Palmer JR, Riboli E, Rohan TE, Sadakane A, Sund M, Tamimi RM, Trichopoulou A, Ursin G, Van Gils CH, Visvanathan K, Weiderpass E, Willett WC, Wolk A, Yuan J-M, Zeleniuch-Jacquotte A, Sandler DP, Swerdlow AJ. Withdrawn [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P1-08-01.
Abstract P1-08-08: Not presented
Authors: Rapiti E , Schaffar R , Bouchardy C , Neyroud-Caspar I , Benhamou S 
Published: May 2019

Abstract
This abstract was not presented at the conference.
Citation Format: Rapiti E, Schaffar R, Bouchardy C, Neyroud-Caspar I, Benhamou S. Not presented [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P1-08-08.
Abstract P1-08-28: Impact of surgery and time to surgery on breast cancer survival in the United States, 2004–2014 (N=2,211,245)
Authors: Singh M , Konduri SD , Bobustuc GC , Rovin RA , Kassam AB 
Published: May 2019

Abstract
Background: Surgery is very common for patients diagnosed with breast cancer. Its impact on survival depends on diagnostic, patient, tumor-related, and other-treatment factors. Moreover, time to surgery from the date of diagnosis is also a critical factor affecting outcome.
Objective: In this study we investigated the impact of surgery on survival in breast cancer patients using two methods: (1) multivariate regression; and (2) propensity score matching. For the patients undergoing surgical intervention, we aimed to identify the optimum time from diagnosis to surgery.
Methods: The study population was taken from the National Cancer Database over the years 2004 through 2014. Of 2,211,245 patients, 99.1% were female, 0.9% male, 85% non-Hispanic white, 10.5% black, 0.7% Hispanic, and 14.5% other races. Mean age of the patient population was 60.0 ± 13.4 years (range: 18–90). The majority of the patients (92.9%) underwent a surgical procedure.
Results: Overall, the patients who did not undergo surgery were 6.7 times more likely to die within the study time period (95% confidence interval [CI]: 6.7–6.8, p&lt;0.001) than those who did. However, after adjusting for patients' demographics, tumor-related factors, cancer stages, and combination of other treatments, the risk for dying of patients without surgery was 2.3 times higher (hazard ratio [HR]: 2.3, 95% CI: 2.3–2.4, p&lt;0.001). In the propensity-matched cohort of 51,630 patients that was divided equally into two groups — those who underwent surgery and those who did not — the risk of mortality remained 2.4 times higher for patients without surgery (HR: 2.4, 95% CI: 2.3–2.4, p&lt;0.001). Regarding time to surgery from the date of diagnosis, patient survival was best for the patients whose time to surgery ranged from 31 to 60 days. The next best timeframe was 61 to 90 days, followed by 30 days or fewer, then 91 to 120 days, and finally 120 and more days (p&lt;0.001).
Conclusion: Using two different statistical methods, surgery is clearly an independent predictor of survival for patients with breast cancer. After matching for other factors, patients not having surgery were more than twice as likely to die as their surgical counterparts. Time to surgery from the date of diagonosis confirmed ealier findings that surgery is most benificial within 2–3 months from the date of diangosis. These findings can provide clinical guidance to clinicians and patients for planning treatment.
Citation Format: Singh M, Konduri SD, Bobustuc GC, Rovin RA, Kassam AB. Impact of surgery and time to surgery on breast cancer survival in the United States, 2004–2014 (N=2,211,245) [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P1-08-28.
Abstract P1-08-30: Triple negative breast cancer: Does ethnicity impact survival?
Authors: Rushton-Marovac M , Zhang T , Song X 
Published: May 2019

Abstract
Background:
Triple negative breast cancer (TNBC) is a heterogeneous disease with poor outcomes relative to hormone positive breast cancer. Observations in the clinical setting lead to the hypothesis that there may be phenotypic differences among ethnic groups. Previous studies have conflicting results; some suggesting no differences, others showing inferior outcomes for black patients (pts). The purpose of this study was to use a population-based approach to examine survival amongst different ethnicities in triple negative breast cancer (TNBC).
Methods
Retrospective population-based study using data from the surveillance epidemiology and end results (SEER) database to identify TNBC cases diagnosed 2010 - 2014. We divided pts into 6 ethnic groups: White, Black, American Indian/Alaskan Native (AIAN), Pacific Islander (PI), Asian and Asian Indian (AI). Primary outcome: overall survival (OS); secondary outcome: breast-cancer specific survival (BCSS). Survival analysis was performed using Cox proportional hazards and Kaplan-Meier models.
Results
31482 pts were included; 22752 (72.3%) were white, 6319 (20.4%) black, 1720 (5.5%) Asian, 262 (0.8%) AI, 179 (0.6%) AIAN, and 150 (0.5%) PI. Asian pts had the best OS (HR 0.82, 95% CI 0.72-0.94), while Black pts had the worst (HR 1.21 95% CI 1.13-1.29) when compared with White pts. Differences between other ethnicities were not statistically significant for OS. Black pts had significantly worse BCSS (HR 1.20, 95% CI 1.12 -1.29); no other ethnicity had statistically significant differences compared to Whites. Comparing Asian with Black pts in multivariate analysis the HR was 0.68 (95% CI 0.59 – 0.79) for OS and 0.71 (95% 0.61 – 0.84) for BCSS. Older age, advanced stage, male sex, and lack of chemotherapy, radiation or surgery were also found to be statistically significant variables in multivariate analysis.
Conclusions
In this large population study, we found Asian pts had significantly better OS and Black pts had significantly worse OS and BCSS. These findings confirm the clinical observation and warrant closer molecular analysis of TNBC phenotypes based on patient's ethnicity. Findings may offer insight into the biology of TNBC and lead to development of innovative treatment options.
Citation Format: Rushton-Marovac M, Zhang T, Song X. Triple negative breast cancer: Does ethnicity impact survival? [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P1-08-30.
Abstract P1-09-03: Withdrawn
Authors: Kotsopoulos J , Zaman T , Lubinski J , Sun P , Salmena L , Narod SA 
Published: May 2019

Abstract
This abstract was withdrawn by the authors.
Citation Format: Kotsopoulos J, Zaman T, Lubinski J, Sun P, Salmena L, Narod SA. Withdrawn [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P1-09-03.
Abstract P1-09-12: TP53 expression in relation to clinical and etiologic factors in breast cancer subtypes
Authors: Yang XR , Abubakar M , Guo C , Koka H , Sung H , Guida J , Deng J , Zhou B , Hu N , Lu N 
Published: May 2019

Abstract
TP53 is a well-known tumor suppressor gene and mutations in TP53 are the most frequent genomic event in most cancers including breast cancer. Recent studies have shown that the frequency, spectrum, timing, and clinical implications of TP53 mutations varied in different molecular subtypes of breast cancer. For example, the frequency of TP53 mutations is the highest in basal-like subtype and lowest in luminal A tumors. However, the evaluation of TP53 protein expression, as a surrogate for TP53 mutations, in large studies in the context of tumor subtypes is limited. In addition, the etiologic relevance of TP53 expression is yet to be investigated. The goal of this study is to evaluate the association of clinical and breast cancer risk factors with TP53 expression, measured using immunohistochemistry (IHC), in breast cancer molecular subtypes. The analysis included 7,226 women with invasive breast cancer who were diagnosed and treated in a tertiary hospital in Beijing, China. Subtypes were defined as Luminal A: ER+ and PR+, HER2–, and low grade (grades 1 or 2); luminal B/HER2–: ER+ and/or PR+, HER2–, and high grade (grade 3); luminal B/HER2+: ER+ and/or PR+, HER2+ (regardless of grade); HER2-enriched: ER–, PR–, and HER2+; Triple-negative (TN): ER–, PR–, and HER2–. As expected, positive TP53 staining showed the lowest frequency in the luminal A (46%) and highest in the TN (61%) and HER2-enriched (63%) subtypes (P-value &lt;0.001). Overall and particularly in luminal A patients, positive TP53 staining was associated with higher frequencies of aggressive tumor features such as higher grade, larger tumor size, higher proliferative index, and EGFR expression. Compared with TP53– patients, TP53+ patients were more likely to have younger ages at onset and increased parity, but these associations were largely driven by the luminal A subtype [OR (95% CI) vs nulliparity = 2.67 (1.59, 4.51); 2.63 (1.52, 4.55); 3.68 (2.01, 6.72) for 1, 2, and ≥3 children, respectively (P-trend = 0.006)]. Luminal A/TP53+ patients were also more likely to have breastfed [OR (95% CI) ever vs never = 1.38 (1.03, 1.85)] than luminal A/TP53– patients. These findings suggest that TP53 IHC staining might be used to further refine the classification of luminal A breast cancer into subgroups with distinct clinical and etiologic relevance.
Citation Format: Yang XR, Abubakar M, Guo C, Koka H, Sung H, Guida J, Deng J, Zhou B, Hu N, Lu N. TP53 expression in relation to clinical and etiologic factors in breast cancer subtypes [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P1-09-12.
Abstract P1-11-14: Efficacy and quality of life analysis of palonosetron vs ondansetron for high and moderate emetogenic chemotherapy for breast cancer
Authors: Arce-Salinas C , Deneken-Hernandez Z , Flores-Diaz D , Gonzalez-Serrano JP , Matus-Santos JA , Ruiz-Garcia E , Calderillo-Ruiz G , Macedo O , Santamaría-Galicia J , Aguilar-Ponce JL , Reynoso-Noverón N 
Published: May 2019

Abstract
Background: Nausea and vomiting are common complications on the chemotherapy (CINV) and can affect the quality of life of the patients. There are various antiemetic regiments that varies in both cost and effectiveness. The aim of this trial is to evaluate the efficacy in acute and delayed CINV of ondansetron vs palonosetron.
Patients and methods: In his was a randomized, open label trial, we included breast cancer patients' candidate to (AC, TC, TCH regimens); arm A received palonosetron, dexamethasone and fosaprepitant and arm B ondansetron, dexamethasone, fosaprepitant; patients who had received previously any chemotherapy or radiotherapy were excluded.Presence of CINV were investigated, as well the ER visits due for CINV and QoL (EORTC QLQ 30 and EORTC B-23) were analyzed during the first cycle of treatment. Local ethics committee approved the trial.
Results: 262 patients were included, 87% received AC and 13% TC; acute control was achieved in 87% and 94% respectively, p=ns and delayed control was achieved in 76% and 86% p=ns, toxicity was similar in both arms. QoL analysis showed no differences in family interaction, social life and financial troubles. ER visits due to severe symptoms were similar p=ns
Conclusions: Palonosetron or ondansetron are equally effective in prevention acute and delayed CINV and they also maintain similar quality of life.
Citation Format: Arce-Salinas C, Deneken-Hernandez Z, Flores-Diaz D, Gonzalez-Serrano JP, Matus-Santos JA, Ruiz-Garcia E, Calderillo-Ruiz G, Macedo O, Santamaría-Galicia J, Aguilar-Ponce JL, Reynoso-Noverón N. Efficacy and quality of life analysis of palonosetron vs ondansetron for high and moderate emetogenic chemotherapy for breast cancer [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P1-11-14.
Abstract P1-12-01: Withdrawn
Authors: Bjelic-Radisic V , Bottomley A , Cardoso F , Cameron D , Brain E , Kuljanic K , de Costa RA , Conroy T , Deville V , Inwald E , Serpentini S , Pinto M , Bleiker E , Arrares J , Duhoux F , Weiss J , Morag O , Lindviksmoen Astrup G , Tomaszweksi K , Velikova G , Pogoda K , Nagele E , Bliem B , Sinai P , Sprangers M , Aaronson N , Greimel E 
Published: May 2019

Abstract
This abstract was withdrawn by the authors.
Citation Format: Bjelic-Radisic V, Bottomley A, Cardoso F, Cameron D, Brain E, Kuljanic K, de Costa RA, Conroy T, Deville V, Inwald E, Serpentini S, Pinto M, Bleiker E, Arrares J, Duhoux F, Weiss J, Morag O, Lindviksmoen Astrup G, Tomaszweksi K, Velikova G, Pogoda K, Nagele E, Bliem B, Sinai P, Sprangers M, Aaronson N, Greimel E. Withdrawn [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P1-12-01.